CN101910141B - 作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物 - Google Patents

作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物 Download PDF

Info

Publication number
CN101910141B
CN101910141B CN2008801240109A CN200880124010A CN101910141B CN 101910141 B CN101910141 B CN 101910141B CN 2008801240109 A CN2008801240109 A CN 2008801240109A CN 200880124010 A CN200880124010 A CN 200880124010A CN 101910141 B CN101910141 B CN 101910141B
Authority
CN
China
Prior art keywords
amino
added
trifluoropentanamide
methyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801240109A
Other languages
English (en)
Chinese (zh)
Other versions
CN101910141A (zh
Inventor
J·E·小斯塔雷特
K·W·吉尔曼
R·E·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101910141(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101910141A publication Critical patent/CN101910141A/zh
Application granted granted Critical
Publication of CN101910141B publication Critical patent/CN101910141B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2008801240109A 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物 Expired - Fee Related CN101910141B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
US60/984118 2007-10-31
PCT/US2008/079798 WO2009058552A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210178082XA Division CN102718689A (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物

Publications (2)

Publication Number Publication Date
CN101910141A CN101910141A (zh) 2010-12-08
CN101910141B true CN101910141B (zh) 2012-12-19

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008801240109A Expired - Fee Related CN101910141B (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物
CN201210178082XA Pending CN102718689A (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210178082XA Pending CN102718689A (zh) 2007-10-31 2008-10-14 作为β淀粉样肽产生的抑制剂的新型α-(N-磺酰氨基)乙酰胺化合物

Country Status (28)

Country Link
US (2) US8084477B2 (enExample)
EP (3) EP2471769A1 (enExample)
JP (1) JP5460605B2 (enExample)
KR (1) KR20100075575A (enExample)
CN (2) CN101910141B (enExample)
AR (1) AR069135A1 (enExample)
AT (1) ATE502022T1 (enExample)
AU (1) AU2008319122A1 (enExample)
BR (1) BRPI0818837A2 (enExample)
CA (1) CA2704360A1 (enExample)
CL (1) CL2008003271A1 (enExample)
CO (1) CO6270332A2 (enExample)
CY (2) CY1112337T1 (enExample)
DE (1) DE602008005636D1 (enExample)
DK (2) DK2295417T3 (enExample)
EA (2) EA016447B1 (enExample)
ES (2) ES2361283T3 (enExample)
HR (2) HRP20110219T1 (enExample)
IL (1) IL205406A0 (enExample)
MX (1) MX2010004319A (enExample)
NZ (1) NZ584545A (enExample)
PE (1) PE20091394A1 (enExample)
PL (2) PL2295417T3 (enExample)
PT (2) PT2205575E (enExample)
SG (2) SG174044A1 (enExample)
SI (2) SI2295417T1 (enExample)
TW (1) TW200927099A (enExample)
WO (1) WO2009058552A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107935957A (zh) * 2017-12-02 2018-04-20 河南龙湖生物技术有限公司 一种合成高纯度沙坦侧链ttbb的方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465861B1 (en) 2001-12-20 2009-05-06 Bristol-Myers Squibb Company Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
EP2408450B1 (en) * 2009-03-19 2013-03-13 Bristol-Myers Squibb Company Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
JP5627038B2 (ja) 2010-03-12 2014-11-19 日本曹達株式会社 ピリジン環含有化合物
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012069428A1 (en) * 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015534553A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換１，５−ベンゾジアゼピノン化合物
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
TWI848951B (zh) 2018-06-01 2024-07-21 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
CA3144324A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
CZ291659B6 (cs) * 1995-11-17 2003-04-16 Warner-Lambert Company Sulfonamidové inhibitory matricových metaloproteináz
PL331338A1 (en) 1996-07-22 1999-07-05 Monsanto Co Thiosulphonamidic metaloprotease inhibitors
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
HK1038915A1 (zh) 1999-01-27 2002-04-04 Wyeth Holdings Corporation 乙炔磺胺硫醇三对甲氧苯基氯乙烯(tace)抑制物
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
IL144781A0 (en) 1999-02-26 2002-06-30 Merck & Co Inc Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
DE60239078D1 (de) * 2001-12-14 2011-03-10 Raytheon Co Präzise justierte linsenstruktur und eine methode zur herstellung derselben
EP1465861B1 (en) * 2001-12-20 2009-05-06 Bristol-Myers Squibb Company Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
RU2004129278A (ru) * 2002-02-28 2005-06-10 Астразенека Аб (Se) Химические соединения
ATE362368T1 (de) * 2003-03-20 2007-06-15 Santhera Pharmaceuticals Ch Substituierte piperidin- und piperazin-derivative als melanocortin-4 receptor modulatoren
TWI336698B (en) * 2003-03-31 2011-02-01 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7144894B2 (en) * 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
RU2008129797A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Способы получения сульфонамид-замещенных спиртов и их промежуточных соединений
BRPI0707742A2 (pt) * 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107935957A (zh) * 2017-12-02 2018-04-20 河南龙湖生物技术有限公司 一种合成高纯度沙坦侧链ttbb的方法
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法

Also Published As

Publication number Publication date
HRP20110219T1 (hr) 2011-04-30
AU2008319122A1 (en) 2009-05-07
US20090111858A1 (en) 2009-04-30
JP2011502153A (ja) 2011-01-20
DE602008005636D1 (de) 2011-04-28
US8350084B2 (en) 2013-01-08
DK2295417T3 (da) 2012-10-15
MX2010004319A (es) 2010-04-30
PL2295417T3 (pl) 2012-11-30
CL2008003271A1 (es) 2009-07-10
NZ584545A (en) 2011-04-29
BRPI0818837A2 (pt) 2015-04-22
CO6270332A2 (es) 2011-04-20
US8084477B2 (en) 2011-12-27
EP2295417A1 (en) 2011-03-16
SG174044A1 (en) 2011-09-29
CY1113346T1 (el) 2016-06-22
US20120088925A1 (en) 2012-04-12
EA201171439A1 (ru) 2012-05-30
PT2205575E (pt) 2011-05-23
CY1112337T1 (el) 2015-12-09
EP2471769A1 (en) 2012-07-04
SG174043A1 (en) 2011-09-29
PT2295417E (pt) 2012-09-26
ATE502022T1 (de) 2011-04-15
JP5460605B2 (ja) 2014-04-02
EA201000714A1 (ru) 2010-10-29
SI2205575T1 (sl) 2011-07-29
CA2704360A1 (en) 2009-05-07
WO2009058552A1 (en) 2009-05-07
CN101910141A (zh) 2010-12-08
EP2295417B1 (en) 2012-07-04
ES2361283T3 (es) 2011-06-15
EP2205575A1 (en) 2010-07-14
PL2205575T3 (pl) 2011-09-30
EA016447B1 (ru) 2012-05-30
DK2205575T3 (da) 2011-07-11
KR20100075575A (ko) 2010-07-02
HRP20120703T1 (hr) 2012-09-30
TW200927099A (en) 2009-07-01
HK1155161A1 (en) 2012-05-11
CN102718689A (zh) 2012-10-10
EP2205575B1 (en) 2011-03-16
SI2295417T1 (sl) 2012-11-30
PE20091394A1 (es) 2009-09-25
AR069135A1 (es) 2009-12-30
ES2390042T3 (es) 2012-11-06
HK1141801A1 (en) 2010-11-19
IL205406A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CN101910141B (zh) 作为β淀粉样肽产生的抑制剂的α-(N-磺酰氨基)乙酰胺化合物
CN102118972B (zh) 鞘氨醇磷酸酯受体的调节剂
EP2408450B1 (en) Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CN102361862A (zh) 用于治疗阿尔茨海默病的噻吩基磺酰胺
EP2408757B1 (en) A novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production
US8093276B2 (en) Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
HK1141801B (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121219

Termination date: 20161014